
    
      Duration of Treatment: The duration of Part I was 26 weeks: 8 weeks of placebo run-in, 2
      weeks of dose titration, 12 weeks of maintenance, and 4 weeks of tapering-off period. The
      duration of Part II was 1 year. The duration of Part III was planned to be 1 year (some
      patients were treated for >1 year). The duration of Part IV was >3 years (patients could
      continue treatment with ESL until market availability).
    
  